Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 23 June 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 23 June 2023 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2023 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (21 June 2023) there were 96,521,209 ordinary shares of 50 pence each in issue, each carrying one vote per share.
|
|
Resolution |
Votes For (incl. votes at the Chairman's discretion) |
% of votes cast |
Votes Against |
|
Votes Withheld* |
Total votes cast | Result |
|
|
|
|
|
|
|
|
|
|
|
| Ordinary resolutions | | | | | | | |
| | | | | | | | | |
| 1
| To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022. | 73,060,750 | 100.00% | 629 | 0.00% | 146,857 | 73,061,379 | PASS |
| 2
| To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2022. | 51,080,127 | 79.93% | 12,826,613 | 20.07% | 9,301,496 | 63,906,740 | PASS |
| 3
| To appoint Dr. Frank Mathias as a Director. | 73,062,102 | 99.81% | 137,244 | 0.19% | 8,890 | 73,199,346 | PASS |
| 4
| To appoint Leone Patterson as a Director. | 72,892,590 | 99.58% | 307,356 | 0.42% | 8,290 | 73,199,946 | PASS |
| 5
| To reappoint Dr. Roch Doliveux as a Director. | 67,536,075 | 92.26% | 5,662,468 | 7.74% | 9,693 | 73,198,543 | PASS |
| 6 | To reappoint Professor Dame Kay Davies as a Director. | 66,057,059 | 90.24% | 7,141,705 | 9.76% | 9,472 | 73,198,764 | PASS |
| 7
| To reappoint Stuart Paynter as a Director. | 72,551,391 | 99.11% | 649,338 | 0.89% | 7,507 | 73,200,729 | PASS |
| 8
| To reappoint Stuart Henderson as a Director. | 66,051,339 | 90.25% | 7,139,682 | 9.75% | 17,215 | 73,191,021 | PASS |
| 9
| To reappoint Dr. Heather Preston as a Director | 64,485,621 | 88.10% | 8,713,178 | 11.90% | 9,437 | 73,198,799 | PASS |
| 10
| To reappoint Robert Ghenchev as a Director. | 73,059,336 | 99.81% | 140,259 | 0.19% | 8,641 | 73,199,595 | PASS |
| 11
| To reappoint Dr. Michael Hayden as a Director. | 67,826,937 | 92.66% | 5,371,827 | 7.34% | 9,472 | 73,198,764 | PASS |
| 12
| To reappoint Catherine Moukheibir as a Director. | 68,240,515 | 93.22% | 4,959,431 | 6.78% | 8,290 | 73,199,946 | PASS |
| 13
| To reappoint Namrata P. Patel as a Director. | 73,140,356 | 99.92% | 59,590 | 0.08% | 8,290 | 73,199,946 | PASS |
| 14
| To appoint PriceWaterhouseCoopers LLP as auditor. | 73,193,707 | 99.99% | 7,290 | 0.01% | 7,239 | 73,200,997 | PASS |
| 15
| To authorise the Directors to agree the remuneration of the auditor. | 73,195,908 | 99.99% | 4,776 | 0.01% | 7,552 | 73,200,684 | PASS |
| 16 | To authorise the Directors to allot shares. | 70,498,713 | 96.31% | 2,702,643 | 3.69% | 6,880 | 73,201,356 | PASS |
|
|
Special resolutions | | | | | | | |
| 17
| To authorise the Directors to disapply pre-emption rights. | 72,202,544 | 98.64% | 996,404 | 1.36% | 9,288 | 73,198,948 | PASS |
| 18
| To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments. | 70,474,362 | 96.28% | 2,721,812 | 3.72% | 12,062 | 73,196,174 | PASS |
| 19
| To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice. | 71,049,162 | 97.06% | 2,150,941 | 2.94% | 8,133 | 73,200,103 | PASS |
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
In addition, further to the announcement by the Company in January, Dr. Siyamak Rasty has stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.
The Board recognises that, whilst resolution 2 was passed with a clear majority at almost 80%, there was also a significant vote against this resolution. The Board will seek to engage with those shareholders who voted against this resolution and it is anticipated that a revised remuneration policy will be presented to shareholders for their approval at the Company's AGM in 2024. In accordance with the UK Corporate Governance Code, an update on the views received from shareholders and details of any further actions taken by the Company will be published no later than 23 December 2023 by way of Stock Exchange Announcement. A summary will also be published in the 2023 Annual Report and Accounts.
-Ends-
|
Enquiries:
Oxford Biomedica plc:
Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488/ E: ir@oxb.com Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com
Consilium Strategic Communications: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi
|
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
